Nasdaq

FDA Approves ArbliTM, the First Ready-to-Use Oral Liquid Formulation of Losartan, from Scienture Holdings, Inc.

Scienture Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its liquid formulation of losartan, branded as ArbliTM (losartan potassium) Oral Suspension, at a ...
Yahoo Finance

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

COMMACK, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced ...
Seeking Alpha

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

TAMPA, FL, April 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value ...
Pharmabiz

Scienture and BlinkRx collaborate to expand patient access to Arbli, an oral suspension formulation of losartan potassium

Scienture Holdings Inc, a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development ...